Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

A relatively old drug -- metformin -- may hold the key to preventing life-threatening illness and bolstering human longevity, ...

There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...

As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions ...

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

In patients with type 2 diabetes (T2D), treatment with oral semaglutide demonstrated a modest but significant reduction in ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.